

HE Dr Bahar Idriss Abu Garda
Minister of Health
Federal Ministry of Health
PO Box 303
Khartoum,
The Republic of Sudan

22 December 2017

Decision Letter: Request for 2018 Renewal of Gavi support for Pneumococcal, Pentavalent, Rotavirus, Meningococcal type A and Inactivated Polio Vaccines

Your Excellency

I am writing in relation to Sudan's request for 2018 renewal of Gavi support to the Menengitis-A, Pneumococcal, Pentavalent and Rotavirus Vaccines, and Inactivated Polio Vaccines that was reviewed by Gavi Secretariat on 14 of December 2017.

Following the recommendations made by the Secretariat Review, I am pleased to inform you that Gavi has **approved** Sudan's request, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

- Appendix A: Financial and Programatic information – Support for Menengitis-A Vaccine (Men-A)
- Appendix B: Financial and Programatic information – Support for Pneumococcal Vaccine (PCV)
- Appendix C: Financial and Programatic information – Support for Pentavalent Vaccine
- Appendix D: Financial and Programatic information – Support for Rotavirus Vaccine
- Appendix E: Financial and Programatic information – Support for Inactivated Polio Vaccine
- Appendix F: Financial and Programatic information – Support for Injection Safety Devices
- Appendix G: Recommendations of the Gavi Secretariat Review

Please do not hesitate to contact my colleague Dr Rehan Hafiz at rhafiz@gavi.org if you have any questions or concerns.

Yours sincerely



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance



The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

**Decision Letter
Sudan - Support for Meningitis A Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan					
2. Grant number: 1820-SDN-28a-X / 16-SDN-08j-Y					
3. Date of Decision Letter: 22/12/2017					
4. Date of the Partnership Framework Agreement: 10/12/2013					
5. Programme title: New Vaccine Support (NVS) - Meningitis A Preventive Routine					
6. Vaccine type: Meningitis A					
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 doses per vial, LYOPHILISED					
8. Programme duration¹: 2016 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)					
	2016-2017	2018	2019	2020	Total²
Programme Budget (US\$)	1,953,597 ³	443,000	1,016,000	1,022,000	4,434,597
10. Vaccine introduction grant (in US\$): US\$ 1,290,159 disbursed on 11 May 2016.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴					
Type of supplies to be purchased with Gavi funds in each year		2016-2017	2018		
Number of Meningitis A vaccines doses				803,500	
Annual Amounts (US\$)		1,953,597 ⁵		443,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable.					
14. Co-financing obligations: Reference code: 1820-SDN-28a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year		2018	2019	2020	
Number of vaccine doses		111,500	288,500	342,000	
Number of AD syringes		39,700	222,600	263,700	
Number of re-constitution syringes		12,300	31,800	37,600	
Number of safety boxes		575	2,825	3,325	
Value of vaccine doses (US\$)		56,352			
Total co-financing payments (US\$) (including freight)		64,000	171,000	202,500	
15. Operational support for campaigns: Not applicable.					
16. Additional reporting requirements: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017

Decision Letter
Sudan - Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan					
2. Grant number: 1820-SDN-12c-X / 12-SDN-08a-Y					
3. Date of Decision Letter: 22/12/2017					
4. Date of the Partnership Framework Agreement: 10/12/2013					
5. Programme title: New Vaccine Support (NVS) - Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose per vial , LIQUID					
8. Programme duration⁶: 2012 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)					
	2012-2017	2018	2019	2020	Total⁷
Programme Budget (US\$)	88,290,906 ⁸	12,303,000	16,517,500	17,235,000	134,346,406
10. Vaccine introduction grant (in US\$): US\$1,015,500 disbursed on 31 May 2013.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁹					
Type of supplies to be purchased with Gavi funds in each year		2012-2017	2018		
Number of Pneumococcal vaccines doses			3,312,500		
Annual Amounts (US\$)		88,290,906¹⁰	12,303,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable.					
14. Co-financing obligations: Reference code: 1820-SDN-12c-X-C. According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2018	2019	2020		
Number of vaccine doses	500,500	757,800	897,800		
Number of AD syringes	517,200	794,200	940,800		
Number of safety boxes	5,700	8,750	10,350		
Value of vaccine doses (US\$)	1,651,333				
Total co-financing payments (US\$) (including freight)	1,726,500	2,615,000	3,098,000		
15. Operational support for campaigns: Not applicable					

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017

**Decision Letter
Sudan - Support for Pentavalent Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan					
2. Grant number: 1820-SDN-04a-X / 07-SDN-08-Y					
3. Date of Decision Letter: 20/12/2017					
4. Date of the Partnership Framework Agreement: 10/12/2013					
5. Programme title: New Vaccine Support (NVS) - Pentavalent Routine					
6. Vaccine type: Pentavalent					
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose per vial, LIQUID					
8. Programme duration¹¹: 2008-2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)					
	2008-2017	2018	2019	2020	Total ¹²
Programme Budget (US\$)	95,368,215 ¹³	4,201,000	4,895,500	4,666,000	109,130,715
10. Vaccine introduction grant (in US\$): US\$100,000 disbursed on 25 April 2008.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁴					
Type of supplies to be purchased with Gavi funds in each year		2008-2017	2018		
Number of Pentavalent vaccines doses			3,623,100		
Annual Amounts (US\$)		95,368,215 ¹⁵	4,201,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: No applicable.					
Co-financing obligations: Reference code: 1820-SDN-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year		2018	2019	2020	
Number of vaccine doses		506,800	709,500	797,500	
Number of AD syringes		538,800	758,100	851,800	
Number of safety boxes		5,950	8,350	9,375	
Value of vaccine doses (US\$)		547,294			
Total co-financing payments (US\$) (including freight)		612,000	836,000	939,500	
14. Operational support for campaigns: Not applicable					

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

15. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
16. Financial clarifications: Not applicable.	
17. Other conditions: Not applicable.	

Signed by,

Hind A. Khatib

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017

**Decision Letter
Sudan - Support for Rotavirus Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan					
2. Grant number: 1820-SDN-13b-X / 10-SDN-08b-Y					
3. Date of Decision Letter: 22/12/2017					
4. Date of the Partnership Framework Agreement: 10/12/2013					
5. Programme title: New Vaccine Support (NVS) - Rotavirus Routine					
6. Vaccine type: Rotavirus					
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 doses schedule					
8. Programme duration¹⁶: 2011 -2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement					
	2011-2017	2018	2019	2020	Total¹⁷
Programme Budget (US\$)	35,464,718 ¹⁸	4,453,500	5,713,500	5,725,500	51,357,218
10. Vaccine introduction grant (in US\$): US\$371,000 disbursed on 24 May 2011.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ¹⁹					
Type of supplies to be purchased with Gavi funds in each year	2011-2017	2018			
Number of Rotavirus vaccines doses			2,143,500		
Annual Amounts (US\$)			35,464,718 ²⁰		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable.					
14. Co-financing obligations: Reference code: 1820-SDN-13b-X-C. According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2018	2019	2020		
Number of vaccine doses	328,500	496,500	588,000		
Value of vaccine doses (US\$)	660,619				
Total co-financing payments (US\$) (including freight)	682,500	1,030,500	1,221,000		
15. Operational support for campaigns: Not applicable					
16. Additional reporting requirements: Not applicable					

¹⁶ This is the entire duration of the Programme.

¹⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁹ This is the amount that Gavi has approved.

²⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable	

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

20 December 2017

**Decision Letter
Sudan - Support for Inactivated Polio Vaccine (IPV)**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan			
2. Grant number(s): 1518-SDN-25c-X / 15-SDN-08h-Y			
3. Date of Decision Letter: 22/12/2017			
4. Date of the Partnership Framework Agreement: 10/12/2013			
5. Programme title: New Vaccine Support (NVS), IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine²¹: Inactivated Polio Vaccine, 10 doses per vial, LIQUID			
8. Programme duration²²: 2015 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total²³
Routine Programme (US\$)	2,104,492 ²⁴	1,346,000	3,450,492
Catch-up vaccination (US\$)			
Total Budget (US\$)	2,104,492	1,346,000	3,450,492
10. Vaccine introduction grant: US\$1,040,500 disbursed on 10 November 2014 as per Decision Letter dated 4 August 2014.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ²⁵			
Number of vaccines to be purchased with Gavi funds	2015-2017	2018	
IPV Routine Programme (doses)		1,622,900	
IPV Catch-up vaccination (doses)			
Annual Amounts (US\$)	2,104,492	1,346,000	
12. Procurement agency: UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Sudan is encouraged to contribute to vaccine and/or supply costs for IPV.			
15. Operational support for catch-up campaigns: Not applicable			
16. Additional reporting requirements:			
Reports and other information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed	15 May		

²¹ Please refer to section 18 for additional information on IPV presentation.

²² This is the entire duration of the Programme.

²³ This is the total amount endorsed by Gavi for 2015 to 2018.

²⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

²⁵ This is the amount that Gavi has approved.

changes in presentation or minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
<p>18. Other conditions: Not applicable</p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Sudan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sudan.</p>	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017

**Decision Letter
Sudan - Support for Injection safety devices**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Sudan					
2. Grant number: 17-SDN-32a-X; 18-SDN-32a-X ; 19-SDN-32a-X ; 20-SDN-32a-X					
3. Date of Decision Letter: 22/12/2017					
4. Date of the Partnership Framework Agreement: 10/12/2013					
5. Programme title: Injection Safety Devices ²⁶					
6. Programme duration²⁷: 2017-2020					
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)					
	2017	2018	2019	2020	Total²⁸
Programme Budget (US\$)	457,652	382,500	487,500	478,500	1,806,152
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ²⁹					
TOTAL injection safety devices to be purchased with Gavi funds in each year		2017	2018		
Number of AD syringes			8,324,200		
Number of re-constitution syringes			88,500		
Number of safety boxes			92,575		
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)		457,652	382,500		
Injection safety devices to be purchased with Gavi funds in each year, by type of support					
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine			2018		
Number of AD syringes				3,423,600	
Number of safety boxes				37,675	
Annual Amounts for injection safety devices for Vaccine (US\$)				155,500	
New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose per vial, LIQUID			2018		
Number of AD syringes				3,852,000	
Number of safety boxes				42,375	
Annual Amounts for injection safety devices for Vaccine (US\$)				174,500	
New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine			2018		
Number of AD syringes				761,700	

²⁶ This does not include vaccines.

²⁷ This is the entire duration of the Programme.

²⁸ This is the total amount endorsed by Gavi for the entire duration of the Programme.

²⁹ This is the amount that Gavi has approved.

Number of safety boxes	8,375
Annual Amounts for injection safety devices for Vaccine (US\$)	34,500
New Vaccine Support (NVS), Meningococcal type A, 10 doses per vial, LYOPHILISED, Routine	
Number of AD syringes	286,900
Number of re-constitution syringes	88,500
Number of safety boxes	4,150
Annual Amounts for injection safety devices for Vaccine (US\$)	18,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
10. Self-procurement: Not applicable.	
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017

Gavi Secretariat Review Recommendations

The Secretariat Review, following its deliberations:

- Urged the country to ensure that immunisation activities reach all regions, including Darfur;
- The approval of the 2017 tranche of HSS funds will be postponed to 2018 until the country has re-imbursed the US\$ 4,869 of unsupported expenditures identified in Gavi Programme Audit in 2016 and committed to be repaid to Gavi by the end of 2017;
- Encouraged the country to complete the implementation of activities agreed in the audit action plan with high priority to the construction, procurement and incentives related activities;
- Encouraged the country to expedite the finalisation of the workplan budget of the relocation exercise to ensure a faster implementation of the HSS and Performance Payment activities;
- Encouraged the country to urgently finalize pending clarification to the Measles follow up campaign and Yellow Fever.